β-Blockade prevents sustained metalloproteinase activation and diastolic stiffening induced by angiotensin II combined with evolving cardiac dysfunction

Circulation Research

Volumn 86, Issue 7, 2000, Pages 807-815

  Senzaki, Hideaki ^a   Paolocci, Nazareno ^a   Gluzband, Yehezkiel A ^b   Lindsey, Merry L ^c   Janicki, Joseph S ^d   Crow, Michael T ^b   Kass, David A ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d AUBURN UNIVERSITY   (United States)

Author keywords

Angiotensin II; Diastole; Heart failure; Metalloproteinase; receptor blocker

Indexed keywords

ANGIOTENSIN; ATENOLOL; COLLAGEN; COLLAGENASE; GELATINASE; ISOPRENALINE; METALLOPROTEINASE;

ADRENERGIC STIMULATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CELL INFILTRATION; CONTROLLED STUDY; DIASTOLE; DOG; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; FIBROBLAST; HEART FAILURE; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HISTOPATHOLOGY; MALE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; ZYMOGRAPHY;

EID: 0034647045     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.86.7.807     Document Type: Article

References (57)

1. Starling RC. The heart failure pandemic: changing patterns, costs, and treatment strategies. Cleve Clin J Med. 1998;65:351-358.
2. Middlekauff HR, Mark AL. The treatment of heart failure: the role of neurohumoral activation. Intern Med. 1998;37:112-122.
3. Ruffolo RR, Feurstein GZ. Neurohormonal activation, oxygen free radicals, and apoptosis in the pathogenesis of congestive heart failure. J Cardiovasc Pharmacol. 1998;32(suppl 1):S22-S30.
4. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
5. Packer M, Bristow MR, Conn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH, U.S. Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1998;334:1349-1355.
6. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, Snavely DB, Chang PI. Randomized trial of losartan versus captopril in patients over 65 with heart failure. Lancet. 1997;349:747-752.
7. Luchner A, Stevens TL, Borgeson DD, Redfield MM, Bailey JE, Sandberg SM, Heublein DM, Burnett JC Jr. Angiotensin II in the evolution of experimental heart failure. Hypertension. 1996;28: 472-477.
8. Sadoshima J, Yuhui X, Slayter HS, Izumo S. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell. 1993;75:977-984.
9. 1 receptor subtype. Circ Res. 1993;73:413-423.
10. 2+ transient and contractile force induced by angiotensin II in aequorin-loaded rabbit ventricular myocardium. Cardiovasc Res. 1998;37: 524-531.
11. Boston DR, Koyama T, Rodriguez-Larrain J, Zou A, Su Z, Barry WH. Effects of angiotensin II on intracellular calcium and contracture in metabolically inhibited cardiomyocytes. J Pharmacol Exp Ther. 1998; 285:716-723.
12. Cheng C-P, Suzuki M, Ohte N, Ohno M, Wang Z-M, Little WC. Altered ventricular and myocyte response to angiotensin II in pacing-induced heart failure. Circ Res. 1996;78:880-892.
13. Goldsmith SR. Angiotensin II and sympathoactivation in heart failure. J Cardiac Failure. 1999;5:139-145.
14. Goldsmith SR, Rector TSBAJ, Garr M, Kubo SH. Effect of angiotensin II on noradrenaline release in the human forearm. Cardiovasc Res. 1994;28:663-666.
15. Clemson B, Gaul L, Gudin S, Campsey M, McConville S, Nussburger J, Zelis R. Prejunctional angiotensin II receptors: facilitation of norepinephrine release in the human forearm. J Clin Invest. 1994;93: 684-691.
16. Brooks VL. Chronic infusion of angiotensin II resets baroreflex control of heart rate by an arterial pressure-independent mechanism. Hypertension. 1995;26:420-424.
17. Henegar JR, Brower GL, Kabour A, Janicki JS. Catecholamine response to chronic ANG II infusion and its role in myocyte and coronary vascular damage. Am J Physiol. 1995;269:H1564-H1569.
18. Henegar JR, Schwanz DD, Janicki JS. Ang II-related myocardial damage: role of cardiac sympathetic catecholamines and β-receptor regulation. Am J Physiol. 1998;275:H534-H541.
19. 2 in regulating cardiac fibroblast collagen turnover. Am J Cardiol. 1995;76:8D-13D.
20. Ohkubo N, Matsubara H, Nozawa Y, Mon Y, Murasawa S, Kijima K, Maruyama K, Masaki H, Tsutumi Y, Shibazaki Y, Iwasaka T, Inada M. Angiotensin type 2 receptors are reexpressed by cardiac fibroblasts from failing myopathic hamster hearts and inhibit cell growth and fibrillar collagen metabolism. Circulation. 1997;96:3954-3962.
21. Brilla CG, Rupp H, Funck R, Maisch B. The renin-angiotensin-aldosterone system and myocardial collagen matrix remodelling in congestive heart failure. Eur Heart J. 1995;16:107-109.
22. Senzaki H, Gluzband YA, Pak PH, Crow MT, Janicki JS, Kass DA. Synergistic exacerbation of diastolic stiffness from short-term tachycardia-induced cardiodepression and angiotensin II. Circ Res. 1998;82:503-512.
23. Spinale FG, Coker ML, Thomas CV, Walker JD, Mukherjee R, Hebbar L. Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure. Circ Res. 1998;82:482-495.
24. Coker ML, Thomas CV, Clair MJ, Hendrick JW, Krombach RS, Galis ZS, Spinale FG. Myocardial matrix metalloproteinase activity and abundance with congestive heart failure. Am J Physiol. 1998;274: H1516-H1523.
25. Thomas CV, Coker ML, Zellner JL, Handy JR, Crumbley AJ3, Spinale FG. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation. 1998;97:1708-1715.
26. Lenarda A, Sabbadini G, Salvatore L, Sinagra G, Pinamonti B, Gregori D, Ciani F, Muzzi A, Klugmann S, Camerini F, the Heart-Muscle Disease Study Group. Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. J Am Coll Cardiol. 1999;33: 1926-1934.
27. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation. 1991;83:1849-1865.
28. Danser AHJ, van Kesteren CAM, Bax WA, Tavenier M, Derkx FHM, Saxena PR, Schalekamp MADH. Prorenin, renin, angiotensinogen, and angiotensin-converting enzyme in normal and failing human hearts: evidence for renin binding. Circulation. 1997;96:220-226.
29. Lee YA, Liang CS, Lee MA, Lindpaintner K. Local stress, not systemic factors, regulate gene expression of the cardiac renin-angiotensin system in vivo: a comprehensive study of all its components in the dog. Proc Natl Acad Sci U S A. 1996;93:11035-11040.
30. Malhotra R, Sadoshima J, Brosius FC, Izumo S. Mechanical stretch and angiotensin II differentially upregulate the renin-angiotensin system in cardiac myocytes in vitro. Circ Res. 1999;85:137-146.
31. Gelband CH, Sumners C, Lu D, Raizada MK. Angiotensin receptors and norepinephrine neuromodulation: implications of functional coupling. Regul Pept. 1997;72:139-145.
32. Griendling KK, Murphy TJ, Alexander RW. Molecular biology of the renin-angiotensin system. Circulation. 1993;87:1816-1828.
33. Freeman GL. Effects of increased afterload on left ventricular function in closed-chest dogs. Am J Physiol. 1990;259:H619-H625.
34. 2-adrenergic receptors. Cardiovasc Drugs Ther. 1999;13:123-126.
35. 1-adrenoceptor blockade enhances the activity of the stimulatory G-protein in human atrial myocardium. Br J Pharmacol. 1999;128:135-141.
36. Eisenhofer G, Friberg P, Rundqvist B, Ouyyumi AA, Lambert G, Kaye DM, Kopin IJ, Goldstein DS, Esler MD. Cardiac sympathetic nerve function in congestive heart failure. Circulation. 1996;93: 1667-1676.
37. Bohm M, La Rosee K, Schwinger RHG, Erdmann E. Evidence for reduction of norepinephrine uptake sites in the failing human heart. J Am Coll Cardiol. 1995;25:146-153.
38. Grimm D, Elsner D, Schunkert H, Pfeifer M, Griese D, Bruckschlegel G, Muders F, Riegger GAJ, Kromer EP. Development of heart failure following isoproterenol administration in the rat: role of the renin-angiotensin system. Cardiovasc Res. 1998;37:91-100.
39. Rona G. Catecholamine cardiotoxicity. J Mol Cell Cardiol. 1985;17: 291-306.
40. Kiuchi K, Shannon RP, Komamura K, Cohen DJ, Blanchi G, Homcy CJ, Vatner SF, Vatner DE. Myocardial β-adrenergic receptor function during the development of pacing-induced heart failure. J Clin Invest. 1993;91:907-914.
41. Bristow MR, Minobe W, Rasmussen R, Larrabee P, Skerl L, Klein JW, Anderson FL, Murray J, Mestroni L, Karwande SV, Fowler M, Ginsburg R. β-Adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms. J Clin Invest. 1992;89:803-815.
42. Iimoto DS, Covell JW, Harper E. Increase in cross-linking of type I and type III collagens associated with volume-overload hypertrophy. Circ Res. 1988;63:399-408.
43. Gunja-Smith ZA, Morales A, Romanelli R, Woessner J. Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy. Am J Pathol. 1996;148:1639-1648.
44. Ronde LE, Ducharme A, Arroyo LH, Aikawa M, Sukhova GH, Lopez-Anaya A, McClure KF, Mitchell PG, Libby P, Lee RT. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation. 1999;99:3063-3070.
45. Parks WC, Mecham RP, eds. Matrix Metalloproteinases. San Diego, Calif:, Academic Press: 1998.
46. Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro: implications for atherosclerotic plaque stability. J Clin Invest. 1996; 98:2572-2579.
47. Bond M, Fabunmi RP, Baker AH, Newby AC. Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-κB. FEBS Lett. 1998;435:29-34.
48. Takeuchi K, Nakamura N, Cook NS, Pratt RE, Dzau VJ. Angiotensin II can regulate gene expression by the AP-1 binding sequence via a protein kinase C-dependent pathway. Biochem Biophys Res Commun. 1990;172:1189-1194.
49. Vu THWZ. Gelatinase B: structure, regulation, and function. In: Parks CWMRP, ed. Matrix Metalloproteinases. San Diego, Calif: Academic Press; 1998:115-148.
50. Griendling KK, Ushio-Fukai M, Lassègue B, Alexander RW. Angiotensin II signaling in vascular smooth muscle: new concepts. Hypertension. 1997;29(pt 2):366-373.
51. Rump AFE, Klaus W. Evidence for norepinephrine cardiotoxicity mediated by superoxide anion radicals in isolated rabbit hearts. Arch Pharmacol. 1994;349:295-300.
52. Reddy HK, Sigusch H, Zhou G, Tyagi SC, Janicki JS, Weber KT. Coronary vascular hyperpermeability and angiotensin II. J Lab Clin Med. 1995;126:307-315.
53. Laine GA, Allen SJ. Left ventricular myocardial edema: lymph flow, interstitial fibrosis, and cardiac function. Circ Res. 1991;68: 1713-1721.
54. Amirhamzeh MMR, Hsu DT, Cabreriza SE, Jia C-X. Spotnitz HM. Myocardial edema: comparison of effects on filling volume and stiffness of the left ventricle in rats and pigs. Ann Thorac Surg. 1997;63:1293-1297.
55. Yotsumoto G, Moriyama Y, Yamaoka A, Taira A. Experimental study of cardiac lymph dynamics and edema formation in ischemia/ reperfusion injury - with reference to the effect of hyaluronidase. Angiology. 1998;49:299-305.
56. Iozzo RV. Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem. 1998;67:609-652.
57. Coker ML, Heung LJ, Morrison AE, Gunasinghe HR, Zellner JL, Crumbley AJ, Spinale FG. Increased extracellular matrix metalloproteinase inducer protein in human cardiomyopathy: relation to matrix metalloproteinase activity. Circulation. 1999;100(suppl I):I-507. Abstract.